The global populating is aging, and approximately 29% of people with diabetes worldwide are aged 65 years and older, ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

H.C. Wainwright analysts on Tuesday maintained their $145 price target and Buy rating for Corcept Therapeutics Incorporated ...

We recently published a list of These 10 Stocks Already Sank in June. In this article, we are going to take a look at where ...